别名 Atriopeptidase、CALLA、CD10 + [13] |
简介 Thermolysin-like specificity, but is almost confined on acting on polypeptides of up to 30 amino acids (PubMed:6349683, PubMed:6208535, PubMed:15283675, PubMed:8168535). Biologically important in the destruction of opioid peptides such as Met- and Leu-enkephalins by cleavage of a Gly-Phe bond (PubMed:6349683, PubMed:17101991). Catalyzes cleavage of bradykinin, substance P and neurotensin peptides (PubMed:6208535). Able to cleave angiotensin-1, angiotensin-2 and angiotensin 1-9 (PubMed:6349683, PubMed:15283675). Involved in the degradation of atrial natriuretic factor (ANF) and brain natriuretic factor (BNP(1-32)) (PubMed:2531377, PubMed:2972276, PubMed:16254193). Displays UV-inducible elastase activity toward skin preelastic and elastic fibers (PubMed:20876573). |
作用机制 AT1R拮抗剂 [+1] |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2015-07-07 |
靶点 |
作用机制 enkephalinase抑制剂 |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2000-09-23 |
作用机制 AT1R拮抗剂 [+1] |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段申请上市 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-12-01 |
开始日期2024-10-14 |
开始日期2024-10-11 |
申办/合作机构 |